FDA Approves Two-Drug Combo Mavyret for HCV in Adolescents FDA Approves Two-Drug Combo Mavyret for HCV in Adolescents

The FDA approved glecaprevir and pibrentasvir (Mavyret, AbbVie) tablets for the treatment of all six hepatitis C virus (HCV) genotypes in children ages 12 to 17 years.FDA Approvals
Source: Medscape Med Students Headlines - Category: Universities & Medical Training Tags: Gastroenterology News Alert Source Type: news